Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (2): 185-186.DOI: 10.3969/j.issn.1673-8640.2019.02.021
Previous Articles Next Articles
Received:
2017-11-06
Online:
2019-02-28
Published:
2019-02-28
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.02.021
组别 | 例数 | 凝血时间 | ||
---|---|---|---|---|
24 h | 48 h | 96 h | ||
正常对照组 | 3 | |||
4 ℃ | 135.24±20.12 | 521.56±63.25 | 1 222.72±156.25 | |
20 ℃ | 150.63±30.05 | 728.69±80.56 | 1 589.26±203.28 | |
患者组 | 5 | |||
4 ℃ | 323.02±42.25 | 862.55±102.26 | 3 213.77±360.41 | |
20 ℃ | 382.24±32.28 | 1 002.30±124.91 | 5 014.25±591.24 |
组别 | 例数 | 凝血时间 | ||
---|---|---|---|---|
24 h | 48 h | 96 h | ||
正常对照组 | 3 | |||
4 ℃ | 135.24±20.12 | 521.56±63.25 | 1 222.72±156.25 | |
20 ℃ | 150.63±30.05 | 728.69±80.56 | 1 589.26±203.28 | |
患者组 | 5 | |||
4 ℃ | 323.02±42.25 | 862.55±102.26 | 3 213.77±360.41 | |
20 ℃ | 382.24±32.28 | 1 002.30±124.91 | 5 014.25±591.24 |
受试者 | 检测次数 | 0 h | 2 h | 6 h | 12 h | 18 h |
---|---|---|---|---|---|---|
正常对照者1 | 3 | 1.5±0.6 | 1.6±0.6 | 1.8±0.3 | 1.9±0.4* | 4.0±0.1* |
正常对照者2 | 3 | 2.2±1.2 | 2.1±0.4 | 2.2±0.5 | 3.0±0.2* | 5.3±0.6* |
正常对照者3 | 3 | 6.0±0.1 | 6.2±0.1 | 6.4±0.5 | 7.4±0.5* | 16.6±1.2* |
患者1 | 3 | 27.8±1.8 | 25.3±2.0 | 27.3±1.0 | 30.5±1.2* | 53.0±3.6* |
患者2 | 3 | 52.2±2.3 | 55.6±3.5 | 50.6±1.2 | 60.3±4.1* | 78.6±5.2* |
患者3 | 3 | 101.8±12.3 | 92.8±7.5 | 102.3±10.2 | 150.2±7.5* | 235.6±12.5* |
患者4 | 3 | 152.6±10.2 | 158.6±9.8 | 165.3±15.2 | 201.3±13.4* | 502.5±20.5* |
患者5 | 3 | 2 013.0±56.3 | 2 010.0±78.0 | 2 115.4±90.3 | 3 211.5.0±110.2* | 5 362.2±120.5* |
受试者 | 检测次数 | 0 h | 2 h | 6 h | 12 h | 18 h |
---|---|---|---|---|---|---|
正常对照者1 | 3 | 1.5±0.6 | 1.6±0.6 | 1.8±0.3 | 1.9±0.4* | 4.0±0.1* |
正常对照者2 | 3 | 2.2±1.2 | 2.1±0.4 | 2.2±0.5 | 3.0±0.2* | 5.3±0.6* |
正常对照者3 | 3 | 6.0±0.1 | 6.2±0.1 | 6.4±0.5 | 7.4±0.5* | 16.6±1.2* |
患者1 | 3 | 27.8±1.8 | 25.3±2.0 | 27.3±1.0 | 30.5±1.2* | 53.0±3.6* |
患者2 | 3 | 52.2±2.3 | 55.6±3.5 | 50.6±1.2 | 60.3±4.1* | 78.6±5.2* |
患者3 | 3 | 101.8±12.3 | 92.8±7.5 | 102.3±10.2 | 150.2±7.5* | 235.6±12.5* |
患者4 | 3 | 152.6±10.2 | 158.6±9.8 | 165.3±15.2 | 201.3±13.4* | 502.5±20.5* |
患者5 | 3 | 2 013.0±56.3 | 2 010.0±78.0 | 2 115.4±90.3 | 3 211.5.0±110.2* | 5 362.2±120.5* |
[1] | 中国医药教育协会感染疾病专业委员会. 感染相关生物标志物临床意义解读专家共识[J]. 中华结核和呼吸杂志,2017,40(4):243-257. |
[2] | 蒋小红. 心力衰竭合并肺部感染患者BNP、IL-6、PCT的变化及其与心功能的关系[J]. 检验医学,2015,30(11):1125-1127. |
[3] | 梁伟,杨晖,吴春芳,等. 不同调脂治疗方案对冠心病患者血脂和IL-6、TNF-α水平的影响[J]. 检验医学,2011,26(3):193-197. |
[4] | KENIS G,TEUNISSEN C,DE JONGH R,et al.Stability of interleukin 6,soluble interleukin 6 receptor,interleukin 10 and CC16 in human serum[J]. Cytokine,2002,19(5):228-235. |
[5] | FLOWER L,AHUJA R H,HUMPHRIES S E,et al.Effects of sample handling on the stability of interleukin 6,tumour necrosis factor-alpha and leptin[J]. Cytokine,2000,12(11):1712-1716. |
[1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
[2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
[3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
[4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
[8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
[9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
[10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
[11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
[14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
[15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||